The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome.

Authors

Amanda McBride, Thomas Jefferson UniversityFollow
Sarah Houtmann, Thomas Jefferson UniversityFollow
Lindsay Wilde, Thomas Jefferson UniversityFollow
Carlos Vigil, University of Iowa
Christine M. Eischen, Thomas Jefferson UniversityFollow
Margaret Kasner, Thomas Jefferson UniversityFollow
Neil Palmisiano, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

3-27-2019

Comments

This article has been peer reviewed. It is the author’s final published version in Frontiers in Oncology, Volume 9, Issue MAR, March 2019, Article number 192.

The published version is available at https://doi.org/10.3389/fonc.2019.00192. Copyright © McBride et al.

Abstract

Avoidance of apoptosis is a key mechanism that malignancies, including acute leukemias and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront AML in an unfit, elderly population. This paper reviews the pre-clinical and clinical data for apoptosis inhibitors currently in development for the treatment of AML, ALL, and MDS.

Recommended Citation

McBride, Amanda; Houtmann, Sarah; Wilde, Lindsay; Vigil, Carlos; Eischen, Christine M.; Kasner, Margaret; and Palmisiano, Neil, "The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome." (2019). Department of Medical Oncology Faculty Papers. Paper 93.
https://jdc.jefferson.edu/medoncfp/93

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

30972300

Language

English